Rhonda Barnes Jordan
Family Medicine · Houston, TXNPI 1548213937
Payments from drug & device makers
Across 413 payments — averaging $21.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$813
- Pfizer$585
- AbbVie$584
- Optinose US, Inc.$479
- Abbott$466
- plus $5K from 28 others
What the payments were for
- Food & beverage$9,028100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 45 | $1,553 |
| GSK | 63 | $813 |
| Pfizer | 45 | $585 |
| AbbVie(2 entities) | 65 | $584 |
| Optinose US, Inc. | 12 | $479 |
| Abbott | 15 | $466 |
| Sanofi-aventis U.S. LLC | 14 | $414 |
| Astellas Pharma US Inc | 16 | $397 |
| Novartis | 28 | $372 |
| Novo Nordisk | 10 | $353 |
| Amgen | 7 | $345 |
| Sunovion Pharmaceuticals Inc. | 25 | $334 |
| Inspire Medical Systems, Inc. | 3 | $277 |
| Sanofi | 2 | $261 |
| Teva Pharmaceuticals USA, Inc. | 2 | $250 |
| Lilly USA, LLC | 9 | $235 |
| Vanda Pharmaceuticals Inc. | 10 | $192 |
| GRT US Holding, Inc. | 2 | $159 |
| Amarin Pharma, Inc. | 4 | $144 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $133 |
| Janssen Scientific Affairs, LLC | 1 | $121 |
| Kyowa Kirin, Inc. | 1 | $120 |
| Gilead | 4 | $110 |
| E.r. Squibb & Sons, L.L.C. | 6 | $98 |
| Arbor Pharmaceuticals, Inc. | 4 | $55 |
| Merck | 2 | $30 |
| Optos, Inc. | 2 | $29 |
| Tersera Therapeutics LLC | 1 | $27 |
| Neurocrine Biosciences, Inc. | 1 | $25 |
| Boehringer Ingelheim | 1 | $17 |
| Hologic Sales And Service, LLC | 1 | $17 |
| Boston Scientific | 1 | $15 |
| Phadia US Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,035 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 80 | $96,507 |
| MounjaroTirzepatide | 53 | $80,493 |
| FarxigaDapagliflozin Propanediol | 68 | $80,313 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 107 | $76,903 |
| JardianceEmpagliflozin | 66 | $70,068 |
| RybelsusSemaglutide | 18 | $42,653 |
| EntrestoSacubitril/Valsartan | 37 | $40,751 |
| XareltoRivaroxaban | 26 | $25,396 |
| LinzessLinaclotide | 23 | $23,215 |
| MyrbetriqMirabegron | 30 | $20,573 |
| EliquisApixaban | 24 | $20,094 |
| TrulicityDulaglutide | 17 | $19,979 |
| Repatha SureclickEvolocumab | 25 | $17,097 |
| TradjentaLinagliptin | 20 | $16,986 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 28 | $13,609 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $353 | $139,15998 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $813 | $104,511172 claims |
| Lilly USA, LLCMounjaro, Trulicity | $235 | $100,47270 claims |
| Boehringer IngelheimJardiance, Tradjenta | $17 | $87,05486 claims |
| AstraZenecaFarxiga | $1,553 | $80,31368 claims |
| NovartisEntresto | $372 | $40,75137 claims |
| Johnson & JohnsonXarelto | $11 | $25,39626 claims |
| AbbVieLinzess | $584 | $23,21523 claims |
| Astellas Pharma US IncMyrbetriq | $397 | $20,57330 claims |
| PfizerEliquis | $585 | $20,09424 claims |
| MerckDulera | $30 | $3,70211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Houston
- Lisa HollowayHouston$30.1M
- Veronica FragosoHouston$24.5M
- Bonnie ColvilleHouston$19.6M
- Oscar de ValleHouston$12.8M
- van TranHouston$11M
- Joe PouzarHouston$10.7M
- Aalia Al-BarwaniHouston$6.8M
- Terence ChangHouston$3.3M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.